Lisata Therapeutics Q3 net loss widens to $37.4M on merger costs; cash $75.5M; LSTA1 trials on track

LISATA THERAPEUTICS, INC.

2022-Q3 EPS reported -$11.28

Net loss $37.4M (Q3 2022) vs $6.9M (Q3 2021), driven by merger-related expenses and stock compensation.
Cash, equivalents and marketable securities $75.5M as of Sept 30, 2022.
R&D expenses $3.4M (-18% YoY) due to XOWNA FREEDOM trial suspension; G&A $3.9M (+39%) on merger costs.
LSTA1 Phase 2b ASCEND and Phase 1b/2 CENDIFOX trials on track to complete enrollment late 2023/early 2024.
HONEDRA (CLI) pre-consultation with PMDA ongoing; XOWNA (CMD) development paused pending strategic partner.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LISATA THERAPEUTICS, INC. reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the three and nine months ended September 30, 2022 and provided a business update.

View on SEC.gov

Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-22-000101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.